Liver Enzymes on Steroids: How to Read Your ALT, AST and GGT

Your bloodwork comes back and ALT is three times the upper limit. You were running an oral compound for five weeks and now the number on the lab report looks alarming. Your doctor says your liver is under stress. The bodybuilding forum says it is fine and to just take some TUDCA.

Both might be wrong. And the reason is that standard liver function tests were never designed for people who squat heavy three days a week while taking 17-alpha alkylated compounds.

This article covers how to actually read your liver markers on cycle, how to tell whether elevated enzymes are from training or real liver damage, which oral steroids carry the highest hepatotoxic risk, and when you should genuinely be concerned.

What Liver Enzymes Actually Measure

A standard liver function panel includes several enzymes and one pigment. Each one tells you something different, and understanding the source tissue matters more than the number itself.

ALT (Alanine Aminotransferase) is the most liver-specific of the common transaminases. It lives primarily in hepatocytes, with smaller amounts in kidney and muscle tissue. When liver cells are damaged or inflamed, ALT leaks into the bloodstream. Standard reference range: 9 to 59 U/L for men (Ceriotti et al., 2010).

AST (Aspartate Aminotransferase) is found in the liver, but also in skeletal muscle, cardiac muscle, kidneys, and red blood cells. This is the critical distinction: AST is not liver-specific. A heavy leg session can spike your AST without a single hepatocyte being involved.

GGT (Gamma-Glutamyl Transferase) lives almost exclusively in the liver and biliary system. Skeletal muscle damage does not affect it. That makes GGT the single most useful marker for bodybuilders trying to determine whether elevated transaminases are from training or from actual liver stress. Reference range: 12 to 68 U/L for men.

ALP (Alkaline Phosphatase) comes from both liver and bone. In young, active athletes with high bone turnover from heavy resistance training, ALP can be mildly elevated without any liver pathology. If ALP is elevated alongside elevated GGT, the source is likely hepatic. If ALP is elevated but GGT is normal, it is probably bone.

Bilirubin is a breakdown product of haemoglobin. Mild elevation with otherwise normal liver enzymes is often Gilbert's syndrome, a benign genetic condition affecting 5 to 10% of the population. Elevated bilirubin alongside elevated liver enzymes signals real hepatic stress, and very high bilirubin (above 50 umol/L) with jaundice requires urgent medical evaluation.

The GGT Trick: Muscle Damage or Real Liver Stress?

This is the most important concept in the article, and the one that most bodybuilding forums, supplement companies, and even many doctors get wrong.

In a study comparing 15 steroid-using bodybuilders, 10 non-using bodybuilders, and 49 hepatitis patients, both groups of bodybuilders showed elevated CK, AST, and ALT with completely normal GGT. Only the hepatitis patients had elevated GGT. The authors concluded that prior reports of anabolic steroid hepatotoxicity "may have been overstated" because normal GGT pointed to muscle, not liver, as the enzyme source (Dickerman et al., 1999).

A separate survey of 84 primary care physicians presented with this exact clinical scenario (elevated AST/ALT/CK, normal GGT in a bodybuilder) found that 63% incorrectly diagnosed liver disease despite the normal GGT, and 56% failed to identify muscle damage despite markedly elevated CK (Pertusi et al., 2001). Your own doctor may make the same mistake.

The Diagnostic Framework

Here is the decision tree for interpreting your liver markers on cycle:

• AST/ALT elevated + GGT normal + CK elevated = muscle damage from training. Not liver stress. This is the most common pattern in bodybuilders and does not require intervention.
• AST/ALT elevated + GGT elevated = liver stress confirmed. The elevation is hepatic in origin. Assess your oral compound use and consider dose reduction or liver support.
• Bilirubin elevated + GGT/ALP elevated + AST/ALT mildly elevated or normal = cholestatic pattern. This is the signature of C17-alpha alkylated steroid injury and is covered in detail below.

Why You Need to Rest Before Bloodwork

A single one-hour weightlifting session causes statistically significant AST and ALT elevation that persists for at least seven days. GGT and ALP remain within normal range throughout (Pettersson et al., 2008).

If you trained the day before your blood draw, your AST and ALT could be 2 to 3 times the upper limit purely from muscle damage. The 48 to 72 hour rest recommendation before bloodwork is the absolute minimum. If you train legs or back heavily, consider waiting a full week for the most accurate liver assessment.

Why Oral Steroids Hit the Liver Harder

Not all anabolic steroids are hepatotoxic. The distinction comes down to one structural modification: 17-alpha alkylation.

When you swallow a steroid, it passes through the gastrointestinal tract and enters the liver via the hepatic portal vein before reaching systemic circulation. This is called first-pass metabolism. The liver's job is to deactivate foreign compounds, and it does this efficiently: unmodified testosterone taken orally has almost zero bioavailability because the enzyme 17-beta-hydroxysteroid dehydrogenase breaks it down on that first pass.

The 17-alpha alkyl group (a methyl or ethyl group added at the C17 position) blocks this enzyme. The compound survives first-pass metabolism, reaches the bloodstream intact, and becomes orally active. The tradeoff is that the drug accumulates in hepatocytes at high concentrations and resists rapid clearance.

The toxic mechanisms are well documented: reactive oxygen species generation leading to mitochondrial damage in hepatocytes, interference with bile transporter proteins, and disruption of bile flow (Bond et al., 2016); (Petrovic et al., 2022). The result is either hepatocellular injury (cell damage) or cholestasis (bile flow obstruction), or both.

Injectable steroids like testosterone enanthate, nandrolone decanoate, boldenone undecylenate, and drostanolone propionate enter the bloodstream via intramuscular injection, bypassing first-pass hepatic metabolism entirely. The LiverTox database from the NIH states explicitly: "Cholestasis has not been described in patients receiving unmodified testosterone by injection or transdermal patch" (LiverTox, 2021).

Injectables are not harmless in every respect, but the liver-specific risk is overwhelmingly concentrated in the 17-alpha alkylated oral compounds.

Compound-by-Compound Hepatotoxicity Ranking

Not all oral steroids carry the same liver risk. The evidence supports a clear tiered ranking based on case reports, clinical data, and mechanistic severity.

Tier 1: Highest Hepatotoxic Risk

Superdrol (methyldrostanolone) is the most commonly implicated compound in modern AAS liver injury case series. In a comprehensive literature review, it was the single most frequently reported compound, producing classic bland cholestasis with median peak bilirubin of 705 umol/L (41 mg/dL), median ALT of only 125 U/L, and acute kidney injury in 43% of cases from bilirubin nephropathy (Dukewich & Stolz, 2024). Before it was classified as a controlled substance, it was sold over the counter as a "dietary supplement."

Halotestin (fluoxymesterone) is among the most hepatotoxic per milligram. In a two-week study at only 20 mg/day, 6 of 9 subjects showed impaired hepatic clearance on sulfobromophthalein testing. It carries FDA warnings for cholestatic jaundice and hepatocellular neoplasms.

Anadrol (oxymetholone) shows clear dose-dependent hepatotoxicity. Clinical trials in HIV-wasting patients documented ALT/AST elevations above 5x the upper limit at doses of 100 to 150 mg/day over 16 weeks, while lower doses (50 mg/day) in elderly men for 12 weeks produced no enzyme elevation (Petrovic et al., 2022). Bodybuilding doses regularly exceed 100 mg/day.

Dianabol (methandrostenolone) has produced acute cholestasis with bilirubin reaching 20.4 mg/dL and AST above 200 U/L in case reports, including at least one documented hepatic failure.

Tier 2: Moderate Risk

Winstrol (stanozolol) can produce severe cholestasis disproportionate to transaminase elevation. One case documented bilirubin of 44.3 mg/dL at admission in a 19-year-old bodybuilder using 50 mg intramuscularly every other day for two months, peaking at 56.6 mg/dL despite treatment, with only modestly elevated transaminases (Stepien et al., 2015). The injectable form of a C17-aa compound does not eliminate liver risk. Recovery required five months after discontinuation.

Turinabol (chlorodehydromethyltestosterone) is 17-alpha alkylated and carries meaningful hepatotoxic potential, though it appears less frequently in severe case reports than the Tier 1 compounds.

Tier 3: Mildest Oral Risk

Anavar (oxandrolone) is the least hepatotoxic of the C17-aa oral steroids. Unlike other orals, approximately 28% of oxandrolone is excreted unchanged in urine rather than being fully hepatically metabolised. Early clinical series showed it produced elevated liver enzymes in some patients but no cases of jaundice. Not risk-free at bodybuilding doses, but substantially milder than Dianabol, Anadrol, or Superdrol.

Primobolan oral (methenolone acetate) uses a C1-methylation and C17-acetate ester for oral bioavailability rather than the standard C17-alpha methyl group. This structural difference significantly reduces its hepatotoxicity compared to classic C17-aa compounds.

Tier 4: Minimal Risk (Injectables)

Testosterone enanthate/cypionate, nandrolone decanoate, boldenone undecylenate, drostanolone propionate, and trenbolone acetate do not undergo first-pass hepatic metabolism and carry minimal to no hepatotoxic risk. Prospective studies of injectable testosterone and nandrolone show all liver enzyme values remaining within normal range.

Cholestasis: The Silent Risk Most Lifters Miss

Most bodybuilders monitor AST and ALT and assume those two numbers tell the whole liver story. They do not. The characteristic injury pattern from C17-alpha alkylated steroids is not hepatocellular damage (high transaminases) but bland cholestasis: obstruction of bile flow.

Cholestasis creates a deceptive lab pattern. Bilirubin commonly rises to 7 to 53 mg/dL while ALT stays below 200 U/L and ALP stays below 2x the upper limit. Both transaminases can be completely normal despite profound jaundice (LiverTox, 2021). If you are only checking AST and ALT, you can miss this entirely.

What It Looks Like

The largest case series from the DILIN network followed 44 young men with bodybuilding supplement-induced liver injury. Every single patient (100%) presented with jaundice. 84% had pruritus (severe itching). 71% required hospitalisation. Despite these severe clinical features, many had only modestly elevated transaminases (Stolz et al., 2019).

Onset is delayed: cholestasis typically develops 4 to 24 weeks after starting a C17-alkylated compound, with a median of 73 days. Symptoms can appear after you have already finished your oral cycle. Recovery is equally slow, with jaundice persisting for several months after discontinuation.

The Genetic Factor

Not everyone faces the same risk. Variants in cholestasis-related genes (ABCB11, ATP8B1, ABCB4) increase susceptibility to drug-induced cholestasis. In the Stolz et al. case series of 44 bodybuilders with supplement-induced liver injury, mutations in these genes accounted for up to 20% of cases. The ABCB11 E297G variant (encoding the bile salt export pump) was found in 2.9% of cases versus 0.04% of ethnically matched controls, a statistically significant enrichment (p=0.0004) (Stolz et al., 2019).

You cannot detect this variant without genetic testing. Some athletes are walking into oral AAS use with a predisposition they do not know about. This is one of the strongest arguments for including bilirubin in every blood panel during an oral cycle, not just AST and ALT.

Peliosis Hepatis

A rarer but more serious complication of prolonged oral AAS use is peliosis hepatis: blood-filled cystic spaces within the liver parenchyma. It was first documented in a bodybuilder by Cabasso (1994) and is associated with oxymetholone, fluoxymesterone, and methyltestosterone (Bagheri & Boyer, 1974).

Peliosis hepatis is entirely asymptomatic until a complication occurs: portal hypertension, intraperitoneal haemorrhage, or hepatic rupture. It does not show up on standard bloodwork. Imaging detects it. This matters for athletes who use oral compounds continuously or for extended cycles.

When Liver Injury Hits the Kidneys

At extreme bilirubin levels (above 40 mg/dL), bile cast nephropathy can cause acute kidney injury. In severe AAS cholestasis cases, AKI developed in up to 43% of patients (Dukewich & Stolz, 2024). If your creatinine starts rising alongside elevated bilirubin on an oral cycle, this is a medical emergency, not a side effect to manage at home.

When to Test and What to Order

Timing and panel selection determine whether your bloodwork gives you useful information or noise. Here is a testing protocol for any cycle that includes oral compounds.

The Panel

Request these markers together. A basic metabolic panel is not enough:

• ALT and AST (transaminases)
• GGT (the differentiator)
• ALP (liver vs bone)
• Total bilirubin (cholestasis detection)
• CK (confirms muscle source when elevated)

The Schedule

Pre-cycle baseline: Get the full panel above before starting any oral compound. This establishes your personal reference point. Without a baseline, you cannot distinguish a new elevation from a pre-existing one.

Week 3 to 4 on the oral compound: This is the first checkpoint. Most hepatocellular enzyme elevations appear within the first 2 to 4 weeks. If AST/ALT are rising but GGT is normal, it is likely muscle. If GGT is also climbing, liver stress is confirmed.

Week 6 to 8 (mid-cycle): Recheck the full panel. This catches progressive elevation and establishes trends. If you are running a long oral cycle (8+ weeks), this checkpoint is critical.

4 to 6 weeks post-cycle: Confirm enzyme normalisation. If you stopped the oral at the end of the cycle, transaminases should be trending back toward baseline. If bilirubin is climbing weeks after you stopped the compound, suspect cholestasis.

Action Thresholds: When to Worry

Not all elevations require the same response. Use these thresholds as a framework, not a rulebook. Context matters: a single mildly elevated ALT at week 4 is different from a steadily climbing trend across multiple draws.

Less than 3x upper limit of normal (ULN): Monitor. This is common on oral compounds, especially if you trained recently. Confirm with GGT. If GGT is normal, likely muscle origin. Continue liver support, retest in 2 to 3 weeks.

3 to 5x ULN with GGT also elevated: Reduce dose or shorten the oral cycle. Add hepatoprotection (TUDCA, NAC). Retest in 2 weeks. If enzymes continue climbing, stop the oral compound.

Greater than 5x ULN: Stop the oral compound. Full stop. This level of elevation with confirmed hepatic origin (elevated GGT) indicates significant liver stress. Continue monitoring until normalisation and consult a physician.

Jaundice, dark urine, pale stools, severe itching: These are clinical signs of cholestasis. Seek immediate medical evaluation regardless of what your AST/ALT numbers show. Remember: cholestasis can present with near-normal transaminases.

The R-ratio can help your doctor characterise the injury pattern. R = (ALT / ALT upper limit) / (ALP / ALP upper limit). R above 5 suggests hepatocellular injury. R below 2 suggests cholestatic injury. R between 2 and 5 is mixed. AAS injury often starts hepatocellular and shifts cholestatic over time.

Liver Support: What Actually Works (and What Doesn't)

Here is where honesty matters. The supplement industry and bodybuilding forums treat liver support as a solved problem: take TUDCA and NAC and your liver is protected. The actual evidence is more nuanced.

No randomised clinical trial has ever tested TUDCA, NAC, silymarin, or any supplement specifically during anabolic steroid use. Every recommendation below is extrapolated from studies in other liver diseases. This does not mean these supplements are useless; it means the certainty level is lower than most people assume.

TUDCA (Tauroursodeoxycholic Acid)

Evidence grade: Moderate (for cholestatic liver disease). Theoretical for AAS context.

TUDCA is a bile acid that displaces toxic hydrophobic bile acids from the bile acid pool. It reduces endoplasmic reticulum stress and activates hepatoprotective pathways through FXR and Nrf2 (Song et al., 2023). A double-blind RCT in 18 patients with liver cirrhosis showed significant reductions in ALT, AST, and ALP at 750 mg/day over six months (Pan et al., 2013).

The mechanistic rationale for AAS-induced cholestasis is strong: oral steroids damage bile transporter proteins, and TUDCA supports bile flow. But this RCT was small (18 completers) and tested liver cirrhosis, not steroid cycles. The mechanistic case is compelling; the direct applicability is unconfirmed.

Dosing (from hepatology trials): 500 to 1,000 mg/day.

NAC (N-Acetyl Cysteine)

Evidence grade: Moderate (for acute liver failure). Weak for prophylactic AAS use.

NAC is the rate-limiting precursor for glutathione synthesis, the liver's primary antioxidant defence. It is the established treatment for paracetamol (acetaminophen) overdose. In a 173-patient RCT of non-acetaminophen acute liver failure, intravenous NAC improved transplant-free survival (40% vs 27% placebo, p=0.043) (Lee et al., 2009).

The critical caveat: that trial used intravenous NAC in hospitalised patients with acute liver failure, not oral capsules taken prophylactically during a cycle. The glutathione pathway rationale is sound, and oral AAS do generate oxidative stress in hepatocytes. But the dose-to-efficacy translation from IV acute care to oral prevention has not been established (Ntamo et al., 2021).

Dosing (from clinical protocols): 600 to 1,200 mg/day.

Milk Thistle (Silymarin)

Evidence grade: Weak.

Silymarin is the most popular liver supplement in bodybuilding and has the weakest outcome data from the trials that should matter most. Two properly designed 48-week RCTs in NASH patients failed to meet their primary endpoints at 700 mg three times daily. One trial found a significant improvement in fibrosis scores (22.4% vs 6.0%, p=0.023) but no benefit on overall histological grade or transaminases (Chan Wah Kheong et al., 2017). The second found no benefit in the intention-to-treat analysis (Navarro et al., 2019).

A large meta-analysis of 26 RCTs pooling 2,375 patients found statistically significant but modest ALT/AST reductions in NAFLD populations (Li et al., 2024). The effect appears context-dependent and has never been tested in drug-induced cholestasis. Milk thistle is widely used because it is cheap and safe, not because it has strong evidence of efficacy.

Dosing (from NASH trials): 420 to 700 mg/day.

The Bottom Line on Liver Support

TUDCA has the strongest mechanistic case for AAS-induced cholestasis specifically. NAC has the strongest clinical data for liver emergencies generally. Neither has been validated in the context it is most commonly used: prophylaxis during a steroid cycle. Monitoring your bloodwork is the one intervention with face-valid justification, because it tells you whether liver stress is actually occurring rather than assuming supplementation is preventing it.

Recovery: How Long Until Enzymes Normalise?

Stop the oral compound and ask yourself: how quickly should your liver markers return to normal?

Transaminases (ALT/AST): In most cases, ALT and AST normalise within 4 to 8 weeks after discontinuing the oral steroid. If enzymes are still elevated beyond 8 weeks and you are not training heavily, further investigation is warranted.

Cholestatic jaundice: This is the slow one. In severe cases, jaundice can persist 5 to 12 months after stopping the compound. The Stolz et al. series documented prolonged cholestasis with bilirubin continuing to rise for up to 28 days after cessation before slowly declining (Stolz et al., 2019). Patience and monitoring are required. Adding more compounds or supplements will not speed bile duct recovery.

AAS-related DILI is not usually fatal. In the largest case series, zero deaths and zero liver transplants occurred. But "not fatal" does not mean "not serious." Hospitalisation rates of 71%, AKI rates up to 43%, and months-long jaundice are serious medical events.

Recovery Monitoring Schedule

• 2 weeks post-oral: Recheck ALT, AST, GGT, bilirubin. Expect transaminases to be trending down.
• 4 to 6 weeks post-oral: Full panel. Most athletes should be near baseline. If not, extend monitoring.
• 3 months post-oral: Final confirmation. If still elevated, consult a hepatologist.
• If jaundice developed: Monthly bilirubin monitoring until resolved. This can take 6+ months in severe cases.

Key Takeaways

• GGT is your best friend. Elevated AST/ALT with normal GGT in a bodybuilder almost always means muscle damage, not liver damage. Always request GGT alongside standard liver panels.
• Not all steroids are hepatotoxic. The risk is concentrated in 17-alpha alkylated oral compounds. Injectable testosterone, nandrolone, boldenone, and drostanolone carry minimal liver risk.
• Superdrol, Halotestin, and Anadrol carry the highest liver risk. Anavar is the mildest oral but is not risk-free at bodybuilding doses.
• Cholestasis is the real danger, and it hides. It can present with near-normal AST/ALT but severely elevated bilirubin. Always include total bilirubin in your panel.
• Rest 48 to 72 hours minimum before bloodwork. Training elevates AST and ALT for up to seven days. False positives waste your time and your doctor's.
• TUDCA and NAC have good mechanistic rationale but no AAS-specific clinical trials. Use them, but do not assume they make oral steroids safe. Monitoring is the intervention that actually tells you what is happening.
• Action thresholds matter. Below 3x ULN, monitor. 3 to 5x with elevated GGT, reduce dose. Above 5x, stop the oral. Jaundice means emergency evaluation.

---

References

1. Ceriotti, F., Henny, J., Queraltó, J., Ziyu, S., Özarda, Y., Chen, B., Boyd, J. C., & Panteghini, M. (2010). Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clinical Chemistry and Laboratory Medicine, 48(11), 1593-1601. PubMed

2. Dickerman, R. D., Pertusi, R. M., Zachariah, N. Y., Dufour, D. R., & McConathy, W. J. (1999). Anabolic steroid-induced hepatotoxicity: is it overstated? Clinical Journal of Sport Medicine, 9(1), 34-39. PubMed

3. Pertusi, R., Dickerman, R. D., & McConathy, W. J. (2001). Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? Journal of the American Osteopathic Association, 101(7), 391-394. PubMed

4. Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008). Muscular exercise can cause highly pathological liver function tests in healthy men. British Journal of Clinical Pharmacology, 65(2), 253-259. PubMed

5. Bond, P., Llewellyn, W., & Van Mol, P. (2016). Anabolic androgenic steroid-induced hepatotoxicity. Medical Hypotheses, 93, 150-153. PubMed

6. Dukewich, M., & Stolz, A. (2024). Anabolic steroid-associated liver injury. Clinical Liver Disease (Hoboken), 23(1), e0196. PubMed

7. Abeles, R. D., Foxton, M., Khan, S., Goldin, R., Smith, B., Thursz, M. R., & Verma, S. (2020). Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated RUCAM score and a comprehensive review of the literature. BMJ Open Gastroenterology, 7(1), e000549. PubMed

8. Stępień, P. M., Reczko, K., Wieczorek, A., et al. (2015). Severe intrahepatic cholestasis and liver failure after stanozolol usage: case report and review of the literature. Clinical and Experimental Hepatology, 1(1), 30-33. PubMed

9. Stolz, A., Navarro, V., Hayashi, P. H., Fontana, R. J., Barnhart, H. X., Gu, J., ... & Hoofnagle, J. H. (2019). Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology and Therapeutics, 49(9), 1195-1204. PubMed

10. Nayagam, J. S., Williamson, C., Joshi, D., & Thompson, R. J. (2020). Review article: liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1. Alimentary Pharmacology and Therapeutics, 52(11-12), 1628-1639. PubMed

11. Cabasso, A. (1994). Peliosis hepatis in a young adult bodybuilder. Medicine and Science in Sports and Exercise, 26(1), 2-4. PubMed

12. Bagheri, S. A., & Boyer, J. L. (1974). Peliosis hepatis associated with androgenic-anabolic steroid therapy: a severe form of hepatic injury. Annals of Internal Medicine, 81(5), 610-618. PubMed

13. El Khoury, C., Sabbouh, T., Farhat, H., & Ferzli, A. (2017). Severe cholestasis and bile cast nephropathy induced by anabolic steroids successfully treated with plasma exchange. Case Reports in Medicine, 2017, 4296474. PubMed

14. Petrovic, A., Vukadin, S., Sikora, R., et al. (2022). Anabolic androgenic steroid-induced liver injury: an update. World Journal of Gastroenterology, 28(26), 3071-3080. PubMed

15. Song, G., Weng, F., Zou, B., et al. (2023). Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. Clinical Science (London), 137(7), 561-577. PubMed

16. Pan, X. L., Zhao, L., Li, L., et al. (2013). Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. Journal of Huazhong University of Science and Technology Medical Sciences, 33(2), 189-194. PubMed

17. Lee, W. M., Hynan, L. S., Rossaro, L., et al. (2009). Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology, 137(3), 856-864. PubMed

18. Ntamo, Y., Ziqubu, K., Chellan, N., et al. (2021). Drug-induced liver injury: clinical evidence of N-acetyl cysteine protective effects. Oxidative Medicine and Cellular Longevity, 2021, 3320325. PubMed

19. Chan Wah Kheong, C., Nik Mustapha, N. R., & Mahadeva, S. (2017). A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology, 15(12), 1940-1949.e8. PubMed

20. Navarro, V. J., Belle, S. H., D'Amato, M., et al. (2019). Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial. PLoS One, 14(9), e0221683. PubMed

21. Li, S., Duan, F., Li, S., & Lu, B. (2024). Administration of silymarin in NAFLD/NASH: a systematic review and meta-analysis. Annals of Hepatology, 29(2), 101174. PubMed